The cannabis withdrawal syndrome

Current Opinion in Psychiatry

Volumn 19, Issue 3, 2006, Pages 233-238

  Budney, Alan J ^a   Hughes, John R ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Cannabis; Dependence; Marijuana; Withdrawal

Indexed keywords

AMFEBUTAMONE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; VALPROATE SEMISODIUM;

DRUG DEPENDENCE; HAMILTON SCALE; HELP SEEKING BEHAVIOR; HUMAN; LABORATORY; NEUROBIOLOGY; NONHUMAN; RELIABILITY; REVIEW; SYMPTOM; TIME; VALIDITY; WITHDRAWAL SYNDROME;

ANIMALS; CANNABIS; DOGS; HUMANS; MARIJUANA ABUSE; MICE; RATS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33748194119     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000218592.00689.e5     Document Type: Review

References (51)

1. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2:244-268.
2. Cottler LB, Schuckit MA, Helzer JE, et al. The DSM-IV field trial for substance use disorders: major results. Drug Alcohol Depend 1995; 38:59-69.
3. Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004; 72:455-466.
4. McRae AL, Budney AJ, Brady KT. Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat 2003; 24:369-376.
5. Stephens RS, Roffman RA, Simpson EE. Adult marijuana users seeking treatment. J Consult Clin Psychol 1993; 61:1100-1104.
6. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 2005; 80:147-159. This article presents a detailed overview of non-human and human studies relevant to pharmacotherapy development for cannabis dependence. The author has provided us with the most current neurobiology and behavioral pharmacology research on cannabinoids and cannabis as it relates to potential medications for cannabis dependence.
7. Piomelli D. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology 2004; 47:359-367. This is a detailed and comprehensive overview of the endogenous cannabinoid system and its implications for understanding cannabis dependence.
8. González S, Cebeira M, Fernández-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 2005; 81:300-318. This review of the animal research on cannabinoids and cannabis as it relates to tolerance and dependence provides the reader with a comprehensive, current understanding of this emerging literature.
9. Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 2005; 81:285-299. This paper provides a thorough review on the cannabinoid self-administration literature that demonstrates the abuse potential of cannabis.
10. Stephens RS, Roffman RA. Adult marijuana dependence. In: Baer JS, Marlatt GA, McMahon RJ, editors. Addictive behaviors across the lifespan: prevention, treatment, and policy issues. Newbury Park, CA: Sage Publications; 1994. pp. 243-273.
11. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol 2002; 42:28S-33S.
12. Lichtman AH, Martin BR. Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 2002; 42:20S-27S.
13. Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 2001; 58:917-924.
14. Haney M, Comer SD, Ward AS, et al. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999; 14:385-394.
15. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999; 14:395-404.
16. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112:393-402.
17. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000; 8:483-492.
18. Budney AJ, Hughes JR, Moore BA, Vandrey RG. A review of the validity and significance of the cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967-1977. This review article provides readers with a history and critical analysis of the scientific literature on cannabis withdrawal. The article focuses on human laboratory and clinical studies published between 1999 and 2004. The authors argue for the validity and importance of the cannabis withdrawal and propose criteria for this syndrome.
19. Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Adv Alcohol Subst Abuse 1990; 9:129-147.
20. Hughes JR, Higgins ST, Hatsukami D, editors. Effects of abstinence from tobacco: a critical review. New York: Plenum Press; 1990.
21. Budney AJ, Novy P, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94:1311-1322.
22. Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend 2005; 78:205-210. This article presents data showing that a substantial percentage of adolescents enrolled in outpatient treatment for cannabis report experiencing multiple cannabis withdrawal symptoms.
23. Crowley TJ, MacDonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct disorder symptoms and substance use disorders. Drug Alcohol Depend 1998; 50:27-37.
24. Mikulich SK, Hall SK, Whitmore EA, Crowley TJ. Concordance between DSM-III-R and DSM-IV diagnoses of substance use disorders in adolescents. Drug Alcohol Depend 2001; 61:237-248.
25. Coffey C, Carlin JB, Degenhardt L, et al. Cannabis dependence in young adults: an Australian population study. Addiction 2002; 97:187-194.
26. Swift W, Hall W, Copeland J. One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug Alcohol Depend 2000; 59:309-318.
27. Swift W, Hall W, Didcott P, Reilly D. Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction 1998; 93:1149-1160.
28. Weisbeck GA, Schuckit MA, Kalmijn JA, et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91:1469-1478.
29. Young SE, Corley RP, Stallings MC, et al. Substance use, abuse and dependence in adolescents: prevalence, symptoms profiles and correlates. Drug Alcohol Depend 2002; 68:309-322.
30. Budney AJ, Bickel WK, Amass L. Marijuana use and treatment outcome among opioid-dependent patients. Addiction 1998; 93:493-503.
31. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat 2001; 20:45-52.
32. Stephens RS, Babor TF, Kadden R, et al. The Marijuana Treatment Project: rationale, design, and participant characteristics. Addiction 2002; 97 (Suppl 1):109-124.
33. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283:401-404.
34. Valverde O, Maldonado R, Valjent E, et al. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 2000; 20:9284-9289.
35. González S, Fernández-Ruiz J, Marzo D, et al. Behavioral and molecular changes elicited by acute administration of SR141716 to delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 2004; 74:159-170. This study is the most recent and well controlled demonstration of cannabinoid withdrawal in animals precipitated by the cannabinoid antagonist, SR141716.
36. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282:221-239.
37. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21:143S-152S.
38. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29:158-170. This human laboratory study demonstrates the efficacy of oral THC for suppressing cannabis withdrawal symptoms. The article provides a good example of the typical methodology used to study cannabis withdrawal in the human inpatient laboratory.
39. American Psychiatric Association. DSM-IV-TR diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2000. pp. 201-204.
40. Vandrey RG, Budney AJ, Hughes JR, Moore BA. Comparison of marijuana, tobacco, and combined withdrawal effects. Miami, FL (Bal Harbor): College on Problems of Drug Dependence; 2003.
41. Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco withdrawal. Am J Addict 2005; 14:54-63. This study shows that a significant subset of adolescents enrolled in treatment for cannabis abuse or dependence report a history of experiencing cannabis withdrawal symptoms similar to what has been observed in studies with adults.
42. Winters KC, Latimer W, Stinchfield RD. The DSM-IV criteria for adolescent alcohol and cannabis use disorders. J Stud Alcohol 1999; 60:337-344.
43. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 1998; 6:419-426.
44. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping-skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000; 68:1051-1061.
45. Lyvers M. Drug addiction as a physical disease: the role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug administration. Exp Clin Psychopharmacol 1998; 6:107-125.
46. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003; 165:157-165.
47. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 13:21-32.
48. Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 1994; 89:1461-1470.
49. deFonseca FR, Carrera MRA, Navarro M, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276:2050-2054.
50. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A 1998; 95:10269-10273.
51. Koob GF, LeMoal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24:97-129.